Jing Xi, MD MPH

3rd Year Fellow

Hometown: Shanghai, China
Medical School: Fudan University, Shanghai, China
Residency: St. Luke’s Hospital, Chesterfield, MO
Research/Academic Interests: Breast Cancer
Bio: Gardening and baking are my two most enjoyable things to do outside of work. After residing in 5 different states from east coast to midwest, my family decided to settle down in St. Louis, which is a fun place to live and great place to raise family. We love hiking in Creve Coeur Lake and Castlewood. We also love cheering on the two championship teams – Chiefs and Blues – at the games.

Selected Publications/Abstracts

  • Wander, S., Zangardi, M., Niemierko, A., Kambadakone, A., Kim L., Xi, J., Pandey, A., Spring, L., Stein, C., Juric D., Kuter, I., Moy, B., Mulvey, T., Vidula, N., Isakoff, S., Yuen, M., Brufsky, A., Ma, C., O’Shuanghnessy, J., Bardia, A. A Multi-center Analysis of Abemaciclib after Progression on Palbociclib in Patients with Hormone Receptor-positive/HER2- Metastatic Breast Cancer. Journal of the National Comprehansive Cancer Network (JNCCN) 2021 Mar 24:1-8: [Epub ahead of print] 
  • Xi, J.*, Hassan, B.*, Katumba, R., Khaddour, K., Govindan, A., Luo, J., Huang, J., Campian, JL. The Predictive Value of Absolute Lymphocyte Counts on Tumor Progression and Pseudoprogression in Patients with Glioblastoma. BMC Cancer 2021 Mar 16:21(1): 285 
  • Xi, J., Cynthia X. Ma. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor? Current Oncology Reports 2020; 22 (6): 57.  
  • Xi, J.*, Oza, A.*, Thomas, S., Ademuyiwa, F., Weilbaecher, K., Suresh, R., Bose, R., Cherian, M., Hernandez-Aya, L., Frith, A., Peterson, L., Luo, J., Krishnamurthy, J., Ma, C. Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer. Journal of the National Comprehansive Cancer Network (JNCCN) 2019; 17(2): 141-147. 
  • Patel, D.*, Xi, J.*, Luo, J., Ma, C., Campian, J. Neutrophil to Lymphocyte Ratio as a Predictor of Survival in Patients with Triple-Negative Breast Cancer. Breast Cancer Research and Treatment 2019; 174(2): 443-452. 
  • Yang, C.*, Xi, J.*, Sheikh, S., Hakim, A., Nadella, S., Dhital, S., MD; Meier, M., Nnanna, O., Meyers, D. A Scoring System for Prediction and Risk Stratification of CO2 Narcosis Among Hospitalized Patients. Emergency Medicine 2018; 8(2):368. 

*co-first author 

BOOK CHAPTERS 

  • Xi, J., Ma, C., Clifton, K. Chapter 13. Breast Cancer. The Washington Manual of Oncology. 4th edition. 2021 
  • Committee on Review of California Institute for Regenerative Medicine (CIRM) (Group Author). The California Institute for Regenerative Medicine: Science, Governance, and the Pursuit of Cures. 2012. Washington, DC: National Academy Press.  
  • Committee on Advancing Pain Research, Care, and Education (Group Author). Relieving Pain in America – A Blueprint for Transforming Prevention, Treatment, and Research. 2011. Washington, DC: National Academy Press.  

SELECTED NATIONAL CONFERENCE PRESENTATIONS  

  • Xi, J., Bagegni, N., Ademuyiwa, F., Frith, A., Suresh, R., Roshal, A., Rigden, C., Hernandez-Aya, L., Peterson, L., Opyrchal, M., Clifton, K., Weilbaecher, K., Bose, R., Ma CX. Circulating tumor DNA mutation profile in relation to palbociclib efficacy in hormone receptor positive and HER2 negative metastatic breast cancer. St. Antonio Breast Cancer Symposium (SABCS), St. Antonio, TX. Dec 8-12, 2020  
  • Wander, S., Han, H., Johnson, G., Lloyd, M., Mao, P., Nayar, U., Kowalski, K., Stein, C., Mariotti, Kim, L., Xi, J., Pandey, A., Dunne, S., Nasrazadani, A., Brufsky, A., Kalinsky, K., Ma, C., O’Shaughnessy, J., Wagle, N., Bardia, A. ESR1 mutation as a potential predictor of abemaciclib benefit following prior CDK4/6 inhibitor (CDK4/6i) progression in hormone receptor-positive (HR+) metastatic breast cancer (MBC): a translational investigation. St. Antonio Breast Cancer Symposium (SABCS), St. Antonio, TX. Dec 8-12, 2020  
  • Wander, S., Zangardi, M., Niemierko, A., Kambadakone, A., Kim L., Xi, J., Pandey, A., Spring, L., Stein, C., Juric D., Kuter, I., Moy, B., Mulvey, T., Vidula, N., Isakoff, S., Yuen, M., Brufsky, A., Ma, C., O’Shuanghnessy, J., Bardia, A. A Multi-center Analysis of Abemaciclib after Progression on Palbociclib in Patients with Hormone Receptor-positive/HER2- Metastatic Breast Cancer. American Society of Clinical Oncology (ASCO) Meeting, Chicago, IL. May 31 – June 4, 2019. Same abstract published in JCO 2019; 37 (15_Suppl) 
  • Xi, J.*, Oza, A.*, Thomas, S., Naughton, M., Ademuyiwa, F., Weilbaecher, K., Suresh, R., Bose, R., Cherian, M., Hernandez-Aya, L., Frith, A., Peterson, L., Luo, J., Krishnamurthy, J., Ma, C. Retrospective Review of Palbociclib Efficacy and Benefit from Subsequent Treatments Following Palbociclib Progression in Patients with Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer.St. Antonio Breast Cancer Symposium (SABCS), St. Antonio, TX. Dec 5-9, 2017. Same abstract published in AACR 2018; 78(4_Suppl) 
  • Tavris, D., Wang, C., Chu H., Xi J., Nie L., Jacobs S., Duggirala H., Pinnow E. Assessing Publication Bias from Clinical Studies of Coronary Artery Stents. International Society for Pharmacoepidemiology (ISPE) Annual Conference, Chicago, IL. Aug 14-17, 2011 
  • Xi, J. An Overlooked Sexual Orientation Health Disparities in Female Breast Cancer Screening. The Michigan Meeting 2010: The Economy and Cancer Health Disparities, Ann Arbor, MI. May 20-22, 2010